

# Arteriovenous Malformation of the Brain: Everything You Need to Know

Evan McNeil, MD, MS

PGY-4 Neurosurgery Resident

Enfolded Clinical and Research Fellow

Open and Endovascular Neurovascular Neurosurgery

BIDMC

Beth Israel Lahey Health




# Financial Disclosures

- [None]
- Looking at you, Medtronic
  - Ball's in your court


# Arteries vs Veins

- Arteries carry blood to capillaries, veins drain blood from capillaries
- Arteries are high pressure, veins are low pressure
- Arteries supply a strictly defined territory, veins share territories


# Arteries vs Veins



Arterial  
Pressure  
Drives  
Perfusion




# Arteries vs Veins






# Arteries vs Veins




# Arteries vs Veins






# Arteries vs Veins




- Flow disruption of the R MCA
- Diffusion weighted MRI shows infarct
- L hemiplegia, L homonymous vision loss, L hemispatial neglect
- Neurons are dead, never coming back

# Arteries vs Veins




- Flow disruption of the L TS
- What clinical symptoms would you expect?
- NONE! The patient is fine!
- There is redundancy of the superficial\* venous system
- Other veins take over!

# Superficial aka “Dural” Venous System



- Very forgiving
- If occluded, blood can find alternative routes
- Dangerous exceptions:
  1. Cortical veins
  2. The confluence of sinuses (torcula)
  3. The posterior third of the superior sagittal sinus

# Deep Venous System



- Much less forgiving
- Occlusion often deadly
- Lacks redundancy



# So what is an AVM?

Brain AVMs are abnormal high-flow artery-to-vein shunts through a nidus without an intervening capillary bed.



# Presentation: what you'll see in practice

Most referrals begin with an event or an incidental imaging finding.

## Hemorrhage

Sudden severe headache, vomiting, altered consciousness, focal deficit, seizure; CT/CTA first in acute settings.

## Seizure

New focal or generalized seizure, especially in a younger adult without prior epilepsy.

## Headache / migraine mimic

Headache alone is nonspecific; vascular imaging is driven by red flags, abnormal neurologic exam, or atypical course.

## Incidental finding

Detected on MRI/CTA ordered for unrelated symptoms; still warrants vascular-neurosurgery review.

### *Action threshold:*

**Urgent ED evaluation for acute neurologic symptoms or imaging findings of hemorrhage; nonurgent referral to a cerebrovascular neurosurgeon/interventional neuroradiology team for stable patients.**

# Natural history: risk is not uniform

Annual hemorrhage risk depends on prior rupture and anatomy

**~1–3%/yr**

All unruptured AVMs

**~4–5%/yr**

Previously ruptured AVMs

**Higher**

deep location, deep drainage,  
associated aneurysm, prior  
hemorrhage

*Translation:*

**“Unruptured” does not mean benign, but the treatment risk may still exceed natural-history risk. “Ruptured” generally changes the risk-benefit discussion toward eventual obliteration if feasible.**

# Grading: why treatment modality varies

Spetzler–Martin estimates microsurgical risk; newer adjunct scales refine selection.

## Spetzler–Martin components

**Size** <3 cm = 1 | 3–6 cm = 2 | >6 cm = 3

**Eloquence** Non-eloquent = 0 | eloquent = 1

**Venous drainage** Superficial only = 0 | deep = 1

## Clinical meaning by SM grade

I-II

often surgical  
candidates

III

individualized

IV-V

conservative/SRS/  
selective surgery

*Key Limitation:*

Grade is not hemorrhage risk. It is mostly treatment-risk language.

# Grading: features specialists care about

The Spetzler–Martin grading scale does not capture all surgical considerations

## Compact vs diffuse nidus

Compact nidus is easier to obliterate surgically

## Presence of a venous varix

Venous aneurysm is a high risk feature for hemorrhage and may push towards urgent treatment


## Surgical corridor

Even some deep lesions can be safely approached


## Endovascular access

Tortuosity

Transarterial vs transvenous embolization




# A note on AVM related aneurysms





# Cerebral proliferative angiopathy

The extreme end of diffuse nidus



# Treatment goals and modalities

A treatment plan is built around complete obliteration with acceptable morbidity.

## Microsurgery

Immediate cure when resection is complete; best for low-grade, superficial, surgically accessible AVMs.

## Stereotactic radiosurgery

Non-open option for small/deep AVMs; obliteration takes years, so hemorrhage risk persists during latency.

## Endovascular embolization

Adjunct to surgery/SRS or targeted treatment of high-risk angioarchitecture; rarely definitive alone.

## Observation / medical management

BP control, seizure management, counseling, and surveillance when treatment risk is high or evidence favors conservative care.

# The Infamous Aruba Trial

Still the best RCT data we have for surgery for unruptured AVMs

**ARUBA randomized unruptured AVMs to medical management alone vs. medical management + intervention**

## What it showed

- Stopped early after higher death/symptomatic stroke in the interventional group
- Extended follow-up continued to favor medical management alone
- A major reason many unruptured AVMs are observed initially

## Why controversy remains

- Short follow-up relative to lifetime hemorrhage risk
- Heterogeneous interventions and center expertise
- Does not mean “never treat”—rather, treat selectively in experienced centers

THE LANCET

Access provided by Harvard University

his journal Journals Publish Clinical Global health Multimedia Events About

ARTICLES • Volume 383, Issue 9917, P614-621, February 15, 2014 [Download Full Issue](#)


Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial

Prof J P Mohr, MD <sup>a,c</sup> • Prof Michael K Parides, PhD <sup>b,c</sup> • Prof Christian Stapf, MD <sup>a,c,d,e,f</sup> • Ellen Moquete, RN <sup>b</sup> • Claudia S Moy, PhD <sup>g</sup> • Jessica R Overbey, MS <sup>h</sup> • et al. Show more

Affiliations & Notes Article Info Linked Articles

# Rupture: acute care first, cure second

Rupture changes urgency of treatment, but not every AVM is obliterated emergently



*Primary care follow up goals:*

**Confirm neurosurgical plan, monitor neurologic recovery, review driving/seizure restrictions, reconcile antithrombotics individually, and support rehab.**



# Microsurgery: The Fastest Cure

Low-grade AVMs are where surgery has its clearest role.

## Best-fit profile

- Spetzler–Martin I–II; select III
- Non-eloquent or safely accessible eloquent lesion
- Prior hemorrhage may favor cure if morbidity acceptable
- Surgery eliminates risk immediately only if complete

## Counseling cautions

- Surgical risk increases with size, eloquence, deep drainage, diffuseness, age
- Institutional experience matters
- Neuropsychological and visual/language deficits may be highly consequential even when mRS is “good”



# Radiosurgery: Delayed Cure Strategy

Best for compact, deeply draining lesions where surgery is riskier.

**Focused radiation causes progressive vessel wall injury and eventual nidus obliteration**

## Latency

Obliteration usually takes 2–4 years; hemorrhage risk persists until angiographic cure.

## Risks

Radiation-induced imaging changes, edema, cysts, delayed deficits; incomplete obliteration may need repeat therapy.

## Ideal lesions

Small volume, compact nidus; deep/eloquent location may favor SRS over surgery.

# Embolization: powerful but usually adjunctive

The catheter is often part of a staged strategy—not the whole treatment.

## Preoperative adjunct

Reduce flow, occlude deep feeders, treat intranidal or flow-related aneurysms, simplify resection.

## Targeted palliation

High-risk angioarchitecture or symptoms when cure is not feasible.

## Before/with SRS

Reduce nidal volume in selected cases; may complicate target definition depending on agent and residual nidus.

## Standalone cure

Possible in select small AVMs, but not the default evidence-based assumption.

Transvenous is probably more efficacious than transarterial

“embolized”  $\neq$  “cured” unless complete obliteration is documented.

# Pushing AVM knowledge forward at BIDMC

Work spanning open, endovascular, and radiation strategies.

## Role and clinical focus

Dr. Ogilvy is Professor of Neurosurgery at Harvard Medical School; BIDMC clinical interests include brain and spinal AVMs, vascular malformations, aneurysms, moyamoya, and stroke.

1

## Multimodal AVM care

Coauthored 12-year experience comparing multimodal treatment outcomes with ARUBA-era benchmarks; emphasized careful selection and multidisciplinary treatment.

2

## Pediatric AVM treatment

Earlier pediatric nongalenic AVM work described combined surgery, radiosurgery, and embolization approaches to improve outcomes.

3

## Radiosurgery / proton beam

Contributed to pediatric and proton-beam stereotactic radiosurgery series evaluating obliteration, hemorrhage, and complications.


4

## Risk stratification

Participated in multicenter validation of the supplemented Spetzler–Martin system and contemporary MISTA consortium propensity-score analyses.

# The Algorithm Simplified

The management question is urgency first, then rupture status, then treatment candidacy.



*Do not skip the “specialist plan” box: AVM decisions are evidence-constrained and center-dependent.*

# The value of “dual trained” neurosurgeons

- Cerebrovascular neurosurgeon
  - A neurosurgeon who specializes in craniotomies for resection or ligation of vascular anomalies like aneurysms, fistulae, or malformations
- Neurointerventionalist
  - A radiologist, neurosurgeon, neurologist, or rarely even cardiologist who performs catheter-based procedures on the blood vessels of the brain
- Interest in endovascular training in neurosurgery is growing



## Selected references

Core evidence and further reading.

---

1. Derdeyn CP et al. Management of Brain Arteriovenous Malformations. *Stroke*. 2017.
2. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. *J Neurosurg*. 1986.
3. Gross BA, Du R. Natural history of cerebral arteriovenous malformations. *J Neurosurg*. 2013.
4. Mohr JP et al. ARUBA: medical management with or without interventional therapy. *Lancet*. 2014; extended follow-up *Lancet Neurol*. 2020.
5. Darsaut TE et al. Treatment of Brain AVMs (TOBAS): pragmatic randomized trial protocol. *Trials*. 2015; [ClinicalTrials.gov NCT02098252](https://clinicaltrials.gov/ct2/show/study/NCT02098252).
6. Kim H et al. Validation of supplemented Spetzler–Martin grading. *Neurosurgery*. 2015.
7. Pulli B et al. Multimodal cerebral AVM treatment: 12-year experience and comparison to ARUBA. *J Neurosurg*. 2019.
8. Walcott BP et al. Proton beam SRS for pediatric cerebral AVMs. *Neurosurgery*. 2014.